Global Epigenetic Antibodies Market Insights Forecasts to 2033 

• The Global Epigenetic Antibodies Market Size was Valued at USD 1.80 Billion in 2023
• The Market Size is Growing at a CAGR of 17.44% from 2023 to 2033 
• The Worldwide Epigenetic Antibodies Market Size is Expected to Reach USD 8.98 Billion by 2033 
• Europe is Expected to Grow the fastest during the forecast period.   

The Global Epigenetic Antibodies Market Size is anticipated to exceed USD 8.98 Billion by 2033, growing at a CAGR of 17.44% from 2023 to 2033.

Market Overview

Specialized instruments called epigenetic antibodies are employed in research to identify and examine epigenetic changes. Changes in gene expression that do not result from modifications to the DNA sequence itself are referred to as epigenetics. Chemical alterations like DNA methylation and histone modification frequently control these alterations. Additionally, the market for epigenetic antibodies is anticipated to be significantly driven by factors such as increased R&D investment, decreasing sequencing time and cost, supportive government funding and initiatives for epigenetics research, and technological advancements in this area. Furthermore, the growing incidence of cancer and the aging of the population are the main causes of epigenetic antibodies. The severity of the crisis is demonstrated by the 1,603,844 new cancer cases and 602,347 cancer-related fatalities that were reported in the US in 2020 alone. This implies that 403 fatalities occur and that there are at least 144 cancer cases for every 100,000 people.

Report Coverage

This research report categorizes the global epigenetic antibodies market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global epigenetic antibodies market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global epigenetic antibodies market.  

Driving Factors

One of the main factors propelling the worldwide epigenetics market is the rising incidence of cancer and chronic illnesses. According to the WHO, there were almost 20 million new instances of cancer and 9.7 million deaths from the disease in 2022, making it one of the major causes of death worldwide. Due in large part to aging populations and lifestyle factors, chronic diseases including diabetes and cardiovascular disorders are also on the rise. Additionally, the study of epigenetics has promise for improving our knowledge of gene expression and how it contributes to ailments such as cancer, neurological conditions, autoimmune diseases, and more. With the goal of utilizing the therapeutic potential of epigenetic pathways, pharmaceutical and biotechnology businesses are investing significant resources in deciphering their intricacies. For instance, in September 2023, together with its original backer Flagship Pioneering, Harbinger Health secured USD 140 million in Series B fundraising. Other international institutional investors included Pictet, Partners Investment, and Catalyst. The new funding will be used by the business to help finish its clinical research for Cancer ORigin Epigenetics-Harbinger Health (CORE-HH).

Restraints & Challenges

The market is severely constrained by the high price of epigenetic tools and services. Mass spectrometers, next-generation sequencing (NGS) devices, and high-throughput screening platforms are examples of advanced technologies that need large capital investments and are frequently out of the price range of smaller research organizations and businesses.

Market Segmentation

The global epigenetic antibodies market share is classified into method and technique.

• The DNA methylation segment is expected to hold the largest share of the global epigenetic antibodies market during the forecast period.                                 

Based on the method, the global epigenetic antibodies market is categorized as DNA methylation, histone modifications, and other methods. Among these, the DNA methylation segment is expected to hold the largest share of the global epigenetic antibodies market during the forecast period. The segment's major contribution is due to the growing prevalence of cancer as well as advancements in PCR, sequencing, and chip-based detection technologies that make it possible to quickly and affordably sequence specific regions of interest.

• The mass spectrometry segment is expected to grow at the fastest CAGR during the forecast period.       

Based on the technique, the global epigenetic antibodies market is categorized as NGS, PCR & qPCR, mass spectrometry, sonication, and other techniques. Among these, the mass spectrometry segment is expected to grow at the fastest CAGR during the forecast period. Through the use of mass spectrometry, researchers can examine epigenetic changes across the genome in detail and identify many marks at once. Compared to conventional antibody-based techniques, which could be constrained in their scope and specificity, this is a major gain.

Regional Segment Analysis of the Global Epigenetic Antibodies Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the global epigenetic antibodies market over the forecast period.

North America is projected to hold the largest share of the global epigenetic antibodies market over the forecast period. The market for epigenetic antibodies in North America is expected to grow due to a number of important factors. The high incidence of chronic illnesses, significant R&D expenditures, and an advanced healthcare system are all contributing to North America's rapidly expanding healthcare industry. With an average cost of $13,493 per person, the United States spent $4.5 trillion on healthcare in 2022, or 17.3% of GDP. With a health spending to GDP ratio of 16.6%, the US led the pack, followed by Germany (12.7%) and France (12.1%). The market is expanding as a result of the biotechnology and pharmaceutical sectors in the area making notable strides in epigenetics research and technology.

Europe is expected to grow at the fastest CAGR growth of the global epigenetic antibodies market during the forecast period. This is because Europe has a robust healthcare infrastructure and large investments are being made in healthcare research and development. Germany (12.8%) and France (12.2%) were the EU members with the greatest healthcare spending percentages of GDP in 2020. When the combined percentage of government programs and required plans/accounts was taken into account, the total current healthcare spending in Germany, Luxembourg, Sweden, and Czechia (where the highest share was reported, at 87.7%) was over 85.0%. In Norway, it was also higher than 85.0%. The market expansion for epigenetic antibodies is being driven by funding initiatives, product development, and supporting research investigations from pharmaceutical firms, private groups, and governmental authorities.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global epigenetic antibodies market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hologic Inc.
• Abcam Plc.
• Zymo Research
• Illumina Inc.
• Active Motif
• Merck Millipore
• PerkinElmer
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Agilent Technologies
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Key Market Developments

• In August 2023, Apton Biosystems (US) was purchased by PacBio (US) in order to accelerate the creation of a high-throughput, short-read, next-generation sequencer.

Market Segment

• This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global epigenetic antibodies market based on the below-mentioned segments: 

Global Epigenetic Antibodies Market, By Method

• DNA Methylation
• Histone Modifications
• Other Methods

Global Epigenetic Antibodies Market, By Technique

• NGS
• PCR & qPCR
• Mass Spectrometry
• Sonication
• Other Techniques

Global Epigenetic Antibodies Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa